| Biomarker ID | 1257 |
| PMID | 24358122 |
| Year | 2013 |
| Biomarker | Occludin |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Cell Lines |
| Subjects | Humans |
| Regulation | Downregulated in: [CAHPV-10 (19.08 fold); DU145 (3.2 fold); PC-3 (4.3 fold)]; Upregulated in LNCaP: (2.2 fold) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | CAHPV-10, DU145, PC-3, LNCaP Vs PNT2 |
| Type of Biomarker | Diagnostic |
| Cohort | Cell lines derived from normal prostate epithelial tissue (PNT2), non-invasive (CAHPV-10) and invasive prostate cancer (LNCaP, DU145, PC-3) were taken for this study |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | CAHPV-10 (p= 0.001); DU145 (p=0.003); PC-3 (0.003); LNCaP: (p = 0.001) |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on human patient cohort |
| Technical Name | NA |